Viatris(VTRS) Prnewswire·2025-03-24 18:41Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Viatris Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Action and Investor Rights - Investors who purchased Viatris securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Viatris [2] Group 2: Financial Impact and Company Announcement - On February 27, 2025, Viatris announced its fourth quarter and full year 2024 financial results, revealing a warning letter and import alert from the FDA affecting 11 products, including lenalidomide and everolimus [3] - The company anticipates a negative impact of approximately 385 million on adjusted EBITDA for 2025 due to the FDA's actions [3] - Following this announcement, Viatris stock price fell by 15.2% on February 27, 2025 [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]